Understanding treatment with VYXEOS, an advancementa,b in secondary AML therapy
Find out why this advancement in chemotherapy may be an appropriate treatment choice for you or your loved one 1 year of age and older with certain types of newly-diagnosed secondary acute myeloid leukemia (sAML): therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
Tim shares his story about secondary AML treatment with VYXEOS
Tim and his family discuss his AML-MRC diagnosis and subsequent treatment with VYXEOS (vix-e-ose).